Leiter L M, Thatte H S, Okafor C, Marks P W, Golan D E, Bridges K R
Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
J Cell Physiol. 1999 Sep;180(3):334-44. doi: 10.1002/(SICI)1097-4652(199909)180:3<334::AID-JCP4>3.0.CO;2-Q.
Chloramphenicol is an antibiotic that consistently suppresses the bone marrow and induces sideroblastic anemia. It is also a rare cause of aplastic anemia. These toxicities are thought to be related to mitochondrial dysfunction, since chloramphenicol inhibits mitochondrial protein synthesis. We hypothesized that chloramphenicol-induced mitochondrial impairment alters the synthesis of ferritin and the transferrin receptor. After treating K562 erythroleukemia cells with a therapeutic dose of chloramphenicol (10 microg/ml) for 4 days, there was a marked decrease in cell surface transferrin receptor expression and de novo ferritin synthesis associated with significant decreases in cytochrome c oxidase activity, ATP levels, respiratory activity, and cell growth. Decreases in the transferrin receptor and ferritin were associated with reduced and unchanged message levels, respectively. The mechanism by which mitochondrial dysfunction alters these important proteins in iron homeostasis is not clear. A global decrease in synthetic processes seems unlikely, since the expression of the cellular adhesion proteins VLA4 and CD58 was not significantly decreased by chloramphenicol, nor were the message levels of beta-actin or ferritin. The alterations were not accompanied by changes in binding of the iron response protein (IRP) to the iron-responsive element (IRE), although cytosolic aconitase activity was reduced by 27% in chloramphenicol-treated cells. A disturbance in iron homeostasis due to alterations in the transferrin receptor and ferritin may explain the hypochromic-microcytic anemia and the accumulation of nonferritin iron in the mitochondria in some individuals after chloramphenicol therapy. Also, these studies provide evidence of a link between mitochondrial impairment and iron metabolism in K562 cells.
氯霉素是一种会持续抑制骨髓并诱发铁粒幼细胞性贫血的抗生素。它也是再生障碍性贫血的罕见病因。这些毒性被认为与线粒体功能障碍有关,因为氯霉素会抑制线粒体蛋白质合成。我们推测,氯霉素诱导的线粒体损伤会改变铁蛋白和转铁蛋白受体的合成。用治疗剂量的氯霉素(10微克/毫升)处理K562红白血病细胞4天后,细胞表面转铁蛋白受体表达和铁蛋白的从头合成显著下降,同时细胞色素c氧化酶活性、ATP水平、呼吸活性和细胞生长也显著降低。转铁蛋白受体和铁蛋白的减少分别与信息水平的降低和不变有关。线粒体功能障碍改变铁稳态中这些重要蛋白质的机制尚不清楚。合成过程的全面下降似乎不太可能,因为氯霉素并未显著降低细胞黏附蛋白VLA4和CD58的表达,β-肌动蛋白或铁蛋白的信息水平也未下降。尽管氯霉素处理的细胞中胞质乌头酸酶活性降低了27%,但这些改变并未伴随着铁反应蛋白(IRP)与铁反应元件(IRE)结合的变化。转铁蛋白受体和铁蛋白的改变导致的铁稳态紊乱可能解释了氯霉素治疗后一些个体出现的低色素小细胞性贫血以及线粒体中非铁蛋白铁的积累。此外,这些研究提供了K562细胞中线粒体损伤与铁代谢之间存在联系的证据。